Basel, 17 December 2004 Novartis Pharma AG announced today the start of a collaboration between Novartis Pharma GmbH and Bayer Vital AG for the commercialization and distribution of EMSELEX (darifenacin hydrobromide), 7.5 mg and 15 mg in Germany. The collaboration is effective following an agreement between Bayer Vital AG and Novartis Pharma GmbH. EMSELEX, a new once-daily M3 selective receptive antagonist (M3 SRA) recently received Marketing Authorization from the European Commission in 25 European member states, plus Norway and Iceland for the treatment of overactive bladder (OAB).
"Bayer Vital has significant expertise of the German urology market, so collaborating with them helps to ensure that EMSELEX will reach physicians quickly and ultimately benefit patients who suffer from overactive bladder," said Kurt Graves, Chief Marketing Officer, Novartis Pharma AG. "EMSELEX is a new effective drug for the treatment of OAB that is selective for the M3 receptors in the bladder, with proven efficacy, good tolerability and with a well established central nervous system and cardiovascular safety profile."
Under the terms of the collaboration, Novartis remains the owner of the marketing authorization for darifenacin, while Bayer Vital gains exclusive commercialization rights for EMSELEX in Germany.
EMSELEX is a once-daily M3 selective receptive antagonist (M3 SRA) oral treatment that works by selectively inhibiting the M3 receptor, the primary mediator of detrusor contraction, whilst sparing the M1 and M2 receptors that are located in various body organs, including the brain and heart. EMSELEX has been shown to effectively reduce the number of weekly incontinence episodes by up to 77% versus placebo.1 Additional clinical trials comparing EMSELEX with placebo showed that EMSELEX does not impair cognitive function and has a cardiovascular safety profile similar to placebo.
To date, 98 clinical trials with EMSELEX haPage: 1 2 3 Related medicine news :1
Contact: Eric Althoff
. Dr. Judah Folkman honored with American Heart Association/Novartis award2
. Drs. Gerald DiBona and John Hall receive American Heart Association/Novartis award3
. Novartis receives FDA approval for Starlix, a new treatment for type 2 diabetes4
. Novartis receives FDA approval for LESCOL XL 80 mg5
. The Gerontological Society of America announces Hartford Fellowship recipients6
. TB Alliance announces new drug discovery program with GlaxoSmithKline7
. ASGE announces grant recipients in annual research awards program8
. American College of Chest Physicians announces new Critical Care Institute9
. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration10
. Department of Energy announces new agreement with USC, national labs and private company11
. ACP announces international medical fellowship